|
DNLI | Denali Therapeutics Inc. |
|
|
DNLI | Denali Therapeutics Inc. |
| Biological Products (no Diagnostic Substances) |
| Book value per $ invested | $ 0.41 |
| Leverage | 10.52% |
| Market Cap | $ 3.0B |
| PE | 0.00 |
| Dividend Yield | 0.00% |
| Profit | $ -420.3m |
| Margin | 0.00% |
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. The company is headquartered in South San Francisco, California.